Navigation Links
Drug combination might offer hope for patients deadly brain tumors
Date:10/18/2007

DURHAM, N.C. -- Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumors blood supply.

According to a new study by researchers at Dukes Preston Robert Tisch Brain Tumor Center, a combination of bevacizumab -- commonly known as Avastin -- and a standard chemotherapy agent, may increase the amount of time GBM patients can survive without tumor growth, and may significantly increase their overall survival.

For this study, we looked at patients whose tumors had returned after initial treatment, and we found that this drug combination could significantly improve outcomes for these people, who are typically given about three to six months to live, said James J. Vredenburgh, M.D., a neuro-oncologist at Duke and lead investigator on the study. These results represent tremendous hope for these patients and their families.

The researchers published their findings in the October 20, 2007 issue of the Journal of Clinical Oncology and an editorial accompanied the publication. The study was funded by the National Institutes of Health, the Preston Robert Tisch Brain Tumor Research Fund and the Bryan Cless Research Fund.

In this pilot study, researchers administered a combination of bevacizumab and irinotecan, a standard chemotherapeutic agent, to 35 patients whose GBMs had returned. Each patient had already been treated with a standard therapy regimen, possibly including surgery, radiation and chemotherapy.

Almost half saw no tumor progression after six months, and almost 80 percent were still alive six months after diagnosis.

Patients with recurrent GBM who are treated with standard therapies, such as chemotherapy alone, have tumor progression at six months in about 75 percent of cases and fewer than 50 percent are alive after six months.

Historically, when GBM recurred, there had typically been very little else we could do, said Vredenburgh. We had one patient on this trial who had been already been told to get his affairs in order; he started the trial and over a year later hes still here, so this is very promising.

Bevacizumab has been heralded as a success in treating several types of cancer, including colorectal and lung cancers. It is one member of a class of drugs called anti-angiogenics, which work by stunting the otherwise rapid growth of blood vessels that feed a tumors growth and spread.

We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently or they work together, with the bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy, Vredenburgh said. Further studies will tease out the exact mechanism of the therapys success and we also hope to study the effectiveness of this treatment in patients with newly diagnosed GBM.

About 8,000 to 10,000 new cases of GBM are diagnosed each year in the United States, and GBMs account for about half of all primary brain tumors, according to Accelerate Brain Cancer Cure, a not-for-profit organization dedicated to hastening the discovery of effective treatments for brain cancer. Less than 30 percent of patients diagnosed with primary GBMs are alive one year after diagnosis, and after 10 years, only 2.3 percent are still alive.

Even when GBMs are effectively treated with surgery or medicines, they return in more than 90 percent of all cases.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Smoking and Breast Cancer - A Deadly Combination
3. The bad combination
4. Drug Combinations May Boost Stroke Risk
5. Combination therapy to treat breast cancer
6. Combination regime may work against prostate cancer
7. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
8. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
9. Combination Therapy Effective In Improving Lung Cancer Survival
10. Combination Therapy Found To Improves Stroke Recovery
11. Combination Therapy Found To Be More Effective In Treating Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... New York, NY (PRWEB) , ... February 12, ... ... latest edition of “Revolutionizing Cancer Care.” , The print component of ... in Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation ...
(Date:2/12/2016)... Washington, DC (PRWEB) , ... February 12, 2016 ... ... announce “Managing High-Cost Drug Categories: Strategies for Health Plans and PBMs,” an upcoming ... strategies to maintain affordability and access in big-dollar therapeutic categories, such as the ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to announce the ... in Norwalk, serves as the host site and directing the camps is PGA Professional ... had successful camps in recent years around Des Moines and are fortunate to have ...
(Date:2/12/2016)... ... ... Healthcare careers in the medical laboratory, nursing, and in the imaging field ... staffing leader Aureus Medical Group during the month of January. Aureus Medical specializes in ... and in travel and direct hire opportunities in other allied health fields. , The ...
(Date:2/12/2016)... Middletown, N.J. (PRWEB) , ... February 12, 2016 ... ... Americans is creating explosive growth in the field of long term care. With ... heightened demand for well-trained healthcare professionals in administrative roles in long term care ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... the Company will ring the Nasdaq Closing Bell at ... York at 4:00 p.m. ET on Tuesday, ... Adrian Adams , will perform the ... to 4:00 p.m. ET.  A live webcast will be ...
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... instruments commonly used in laboratories. These may range from ... condensers. Laboratory glassware is made from borosilicate glass because ... Laboratory plasticware, on the other hand, started gaining popularity ... it was easier to replace glass with plastic in ...
Breaking Medicine Technology: